Embecta Stock News
$5.79
2.30%
NYSE, Oct 01, 04:00 pm EDT.
Closed.
Index
Industry
Embecta Stock News
In September, embecta will participate in the Wells Fargo 2026 Healthcare Conference and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026.
A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category. NEW YORK, Aug. 18, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta C...
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) on behalf of investors that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Embecta a...
A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category. NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta C...
PARSIPPANY, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported third quarter fiscal 2026 financial results.
PARSIPPANY, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 for each issued and outstanding share of the Company's common stock.
PARSIPPANY, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that Nimish Muzumdar has been named the company's Senior Vice President and President, North America, effective June 15, 2026.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
